



## **FOR IMMEDIATE RELEASE**

### **Catabasis to Present CAT-2003 Data at Upcoming Lipid Conferences**

CAMBRIDGE, Mass., April 25, 2014 – [Catabasis Pharmaceuticals Inc.](http://www.catabasis.com) today announced the upcoming presentation of clinical and preclinical data for its lead candidate, CAT-2003, further defining its mechanism of action in the treatment of severe hypertriglyceridemia and chylomicronemia syndromes. Data from the Phase 1 study of CAT-2003 will be presented in an oral session at the National Lipid Association (NLA) Scientific Sessions 2014 in Orlando, FL, and preclinical data will be presented in one oral session and one poster session at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions in Toronto, Ontario.

Details of the presentations are as follows:

#### **NLA**

**Abstract:** #119

**Presenter:** Joanne Donovan, M.D., Ph.D., chief medical officer at Catabasis

**Title:** *Phase 1 Single and Multiple Ascending Dose Study of CAT-2003, a Novel Activator of Lipoprotein Lipase, Decreases Postprandial Triglycerides*

**Date:** Friday, May 2, 2014, 12:35 p.m. EDT

**Location:** Hyatt Regency Grand Cypress Hotel, Orlando, FL

#### **ATVB**

**Abstract:** #75

**Presenter:** Michael Zimmer, Ph.D., senior scientist at Catabasis

**Title:** *CAT-2003 is a Novel Small Molecule that Inhibits Proprotein Convertase Subtilisin/Kexin Type 9 Production and Lowers Non-High-Density Lipoprotein Cholesterol*

**Date:** Thursday, May 1, 2014, 10:45-11:00 a.m. EDT

**Location:** Sheraton Centre Toronto Hotel, Toronto, Ontario

**Abstract:** #73

**Presenter:** Feng Liu, Ph.D., principal scientist at Catabasis

**Title:** *CAT-2003 is a Novel Small Molecule that Activates Lipoprotein Lipase and Reduces Fasting and Postprandial Triglycerides*

**Date:** Thursday, May 1, 2014, 5:30 p.m. EDT

**Location:** Sheraton Centre Toronto Hotel, Toronto, Ontario

#### **About CAT-2003**

CAT-2003 is an oral, small molecule conjugate of niacin and EPA designed to treat chylomicronemia syndromes and severe hypertriglyceridemias. CAT-2003 raises lipoprotein lipase (LPL) and reduces triglycerides by modulating the Sterol Regulatory Element Binding Protein (SREBP) pathway: SREBP is a key regulator of lipid synthesis and clearance. CAT-



2003 leverages Catabasis' proprietary SMART Linker technology to enable selective intracellular delivery and synergistic activity of the active components. CAT-2003 is currently in Phase 2 clinical development.

### **About Catabasis**

Catabasis Pharmaceuticals is developing new medicines to treat patients with severe lipid disorders and rare diseases by applying its pathway pharmacology platform. The Company's mission is to address difficult-to-treat diseases through the simultaneous modulation of multiple targets in a disease pathway. For more information on our technology and pipeline of drug candidates, please visit [www.catabasis.com](http://www.catabasis.com).

###

### Corporate and Media Contact

Amy Lynch

Catabasis Pharmaceuticals Inc.

T: (617)-349-1971

[alynch@catabasis.com](mailto:alynch@catabasis.com)